Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease) by Phernambucq, E C J et al.
Multicenter phase II trial of accelerated cisplatin and high-dose
epirubicin followed by surgery or radiotherapy in patients with
stage IIIa non-small-cell lung cancer with mediastinal lymph node
involvement (N2-disease)
ECJ Phernambucq
1, B Biesma
2, EF Smit*,1,3, MA Paul
4, A vd Tol
5, FM Schramel
6, RJ Bolhuis
7 and PE Postmus
1
1Department of Pulmonary Diseases, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands;
2Department of Pulmonary Diseases,
Jeroen Bosch Hospital, PO Box 90153, 5200 ME ‘s-Hertogenbosch, The Netherlands;
3Department of Pulmonary Diseases, Martini Hospital, PO Box
30033, 9700 RM Groningen, The Netherlands;
4Department of Surgery, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands;
5Department of Surgery, Martini Hospital, PO Box 30033, 9700 RM, Groningen, The Netherlands;
6Department of Pulmonary Diseases, St Antonius
Hospital, PO Box 2500, 2430 EM, Nieuwegein, The Netherlands;
7Department of Surgery, Jeroen Bosch Hospital, PO Box 90153, 5200 ME
‘s-Hertogenbosch, The Netherlands
To assess the therapeutic activity of accelerated cisplatin and high-dose epirubicin with erythropoietin and G-CSF support as
induction therapy for patients with stage IIIa-N2 non-small-cell lung cancer (NSCLC). Patients with stage IIIa-N2 NSCLC were
enrolled in a phase II trial. They received cisplatin 60mgm
 2 and epirubicin 135mgm
 2 every 2 weeks for three courses combined
with erythropoietin and G-CSF. Depending on results of clinical response to induction therapy and restaging, patients were treated
with surgery or radiotherapy. In total, 61 patients entered from March 2001 to April 2004. During 169 courses of induction
chemotherapy, National Cancer Institute of Canada (NCI-C) grade III/IV leucocytopenia was reported in 35 courses (20.7%), NCI-C
grade III/IV thrombocytopenia in 26 courses (15.4%) and NCI-C grade III/IV anaemia in six courses (3.6%). Main cause of cisplatin
dose reduction was nephrotoxicity (12 courses). Most patients received three courses. There were no chemotherapy-related deaths.
Three patients were not evaluable for clinical response. Twenty-eight patients had a partial response (48.3%, 95% CI: 36–61.1%), 24
stable disease and six progressive disease. After induction therapy, 30 patients underwent surgery; complete resection was achieved
in 19 procedures (31.1%). Radical radiotherapy was delivered to 25 patients (41%). Six patients were considered unfit for further
treatment. Median survival for all patients was 18 months. Response rate of accelerated cisplatin and high-dose epirubicin as induction
chemotherapy for stage IIIa-N2 NSCLC patients is not different from more commonly used cisplatin-based regimen.
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At present, treatment options for patients with stage IIIa-N2 non-
small-cell lung cancer (NSCLC) are unclear. Whether surgery after
induction therapy is of value for unselected patients with stage
IIIa-N2 NSCLC is doubtful as in two recently presented large phase
III trials no survival advantage for patients treated with definite
chemoradiation as compared to the same treatment plus resection
was found (Albain et al, 2005). In addition, no survival advantage
was found for patients treated with surgery compared to thoracic
radiation both after a response to induction chemotherapy (Van
Meerbeeck et al, 2005).
In resectable stage IIIa-N2 NSCLC, the role of induction
chemotherapy has been investigated in phase III randomised
studies, comparing induction chemotherapy followed by surgery
with surgery alone. In two small studies a survival benefit was
found for the patients treated with induction chemotherapy (Roth
et al, 1998; Rosell et al, 1999). Since then, a number of single arm
phase II trials have been reported aiming to identify optimal
chemotherapy and subgroups of patients that seem to benefit most
of this treatment. For instance, a recent phase II trial reported
upon the combination docetaxel–cisplatin as induction treatment
followed by surgical resection. Mediastinal downstaging and
complete resection proved to be very strong positive prognostic
factors for survival, and 3-years survival of patients receiving
neoadjuvant therapy plus complete resection was 70% (Betticher
et al, 2003).
However, the optimal combination and dosage of induction
chemotherapy is still unknown. Within past induction trials,
cisplatin was thought to be an essential part of the combinations
used but the other drugs necessary to improve response rate and
survival were not identified. An alternative approach might be
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sdose intensification of existing regimes. In NSCLC, the value of
dose intensification is unknown. A feasibility and efficacy study of
dose intensification of cisplatin and epirubicin in patients with
relapsed NSCLC demonstrated that epirubicin can be escalated to
135mgm
 2 every 2 weeks provided that granulocyte-colony
stimulating factor (G-CSF) support was added to prevent severe
myelosuppression (Huisman et al, 2001). Response rate in this
study was 33% (95% CI: 15–51%), which generated interest in
evaluating this schedule as a first-line regimen for stage IIIa-N2
NSCLC and lead to this phase II trial. The schedule also is an
attractive treatment option because it can be completed within a
short time period. Owing to the frequently reported anaemia in the
feasibility and efficacy study, erythropoietin was included in
the trial as additional haematological support. In addition, the
beneficial effects of erythropoietin on anaemia, functional status
and quality of life of cancer patients receiving chemotherapy have
been demonstrated by several large randomised (Abels, 1993;
Cascinu et al, 1995; Savonije et al, 2005) and nonrandomised
studies (Glaspy et al, 1997; Demetri et al, 1998). In this paper, the
results from a multicenter phase II trial of accelerated cisplatin and
high-dose epirubicin with G-CSF and erythropoietin support in
stage IIIa-N2 NSCLC are reported.
MATERIALS AND METHODS
Patient criteria and study design
Between March 2001 and April 2004, patients with measurable
stage IIIa-N2 NSCLC were entered in this prospective, nonrando-
mised phase II trial. Stage of disease had to be pathologically
proven or confirmed in a multidisciplinary team of medical
doctors. Methods to obtain pathological proof for mediastinal
lymph node involvement were mediastinoscopy, thoracotomy,
endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
or bronchoscopy with transbronchial needle aspiration (TBNA).
Eligible patients were over 18 years old and had adequate
haematological, renal and hepatic functions at the start of
chemotherapy. Exclusion criteria were signs of cardiac failure,
signs of active infection at the start of treatment, Eastern
Cooperative Oncology Group (ECOG) performance status 3–4,
other stage, and previous chemotherapeutic treatment. Ethics
committees approved the trial at each participating center
and written informed consent had to be obtained from all
patients.
After pretreatment examination, patients received cisplatin
60mgm
 2 and epirubicin 135mgm
 2 both in 250ml NaCl 0.9%
on day 1 as an intravenous infusion for 30min every 14-days for
three consecutive courses. Haematopoietic growth factors were
administered as erythropoietin subcutaneous (s.c.) at a dose of
30000IE one time per week and G-CSF s.c. at a dose of
300mgday
 1 for patients with a body weight o60kg and
480mgday
 1 for patients with a body weight X60kg on days
3–12 of each course. To control emesis, ondansetron HCl and
dexamethasone were administered intravenously two times per
day in a dose of 8mg and 20mg, respectively. On days 2 and 3,
patients received three times per day metoclopramide 20mg rectal.
Toxicity was measured according to the National Cancer Institute
of Canada (NCI-C) grading system. Cisplatin dose was modified
if creatinine clearance (using Cockroft-Gault formula) fell below
60mlmin
 1, in case of significant hearing loss as demonstrated by
audiogram, or neurotoxicity NCI-C grade II/III. Epirubicin
dose was reduced to 120mgm
 2 when leucocytopenia and/or
thrombocytopenia NCI-C grade IV lasting for more than 5 days
occurred, in case of neutropenic fever and any other NCI-C grade
III toxicity other than alopecia. The next chemotherapy course had
to be postponed for 1 week with a maximum of 2 weeks in case of
insufficient bone marrow recovery (leucocytes o3 10
9l
 1 and/or
platelets o100 10
9l
 1). Follow-up investigations consisted of
physical examination every 2 weeks; haemoglobin, white blood cell
counts, differential counts and platelets on days 10 and 14 and
liver/renal function before every course. Finally, chest ro ¨ntgeno-
grams (X-chest) were performed before every course, computer
tomogram of the chest (CT-thorax) and fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) before first course and
after three cycles. CT-thorax and X-chest were used for measuring
clinical response according to the response evaluation criteria in
solid tumors (RECIST) (Therasse et al, 2000). At least two courses
had to be completed for evaluation of clinical response, which was
typically assessed after two of three courses. Complete response
was defined as complete disappearance of all known tumour
lesions. A partial response (PR) was defined as either (a) at least a
30% decrease in the sum of the longest diameter (LD) of target
lesions taking as reference the baseline sum LDs or (b) complete
disappearance of target lesions, with persistence (but not
worsening) of one or more nontarget lesions. Progressive disease
(PD): at least a 20% increase in the sum of LD of target lesions
taking as reference the smallest sum LD recorded since the
treatment started or the appearance of one or more new lesions
and/or unequivocal progression of existing nontarget lesions. And
finally, if there was neither sufficient shrinkage to qualify for PR
nor sufficient increase to qualify for PD taking as references the
smallest sum LD, it was defined as stable disease. This study
was based on the Simon one sample two-stage testing procedure
(Simon, 1989). A response rate of 75% or more warranted
further investigation of the chemotherapy regimens used, and a
response rate of 55% or less warranted rejection. The upper limit
of 75% was chosen because it is close to the observed response rate
of the gemcitabine–cisplatin combination which is the most
widely used induction regimen on the European continent (Van
Zandwijk et al, 2000). In addition, since it is intensified
chemotherapy that is applied with potentially more severe side
effects we choose to set the upper limit on 75% for the power
calculation of the study.
Restaging and postinduction treatment
Restaging had to be performed to decide whether surgery or
radiotherapy was the best therapeutic option after induction
chemotherapy. Methods used for restaging were CT-thorax, FDG-
PET, X-chest, mediastinoscopy and EUS-FNA.
Patients without persisting N2-disease and who were medically
fit to proceed to surgery underwent thoracotomy, with the
intention to achieve a complete resection, preferably by lobectomy
or else pneumonectomy. Mediastinal lymph node dissection was
performed with each resection. Patients with incomplete or no
resection at thoracotomy were offered postoperative radiotherapy.
The patients with persisting N2-disease and/or PD at restaging
were treated with radical thoracic radiotherapy, typically consist-
ing of 46Gy in 23 fractions delivered to the primary field and
13.8Gy in 23 fractions delivered as a boost on the tumour. This
total of 59.8Gy was applied in a 5daysweek
 1 scheme with
duration of 5 weeks. Lower dosages were delivered as palliative
radiotherapy.
Statistical analysis
Time to postinduction treatment is dated from first day of last
course of induction chemotherapy to the date of thoracotomy or
first day of radiotherapy.
Survival is calculated from day 1 of the first course (start
treatment) until death or 1 May 2005. The survival curve is
estimated by the Kaplan–Meier method (Kaplan and Meier, 1958).
Disease-free survival is defined as the period from start treatment
to the date of disease progression, relapse or death.
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Patient characteristics
In total, 62 consenting patients were entered from March 2001 to
April 2004 in four hospitals in The Netherlands. One patient
withdrew informed consent before the start of study treatment.
In Table 1, the characteristics of all remaining 61 patients are
summarised. The study group consisted of 44 men and 17 women
with a median age of 63 years (range 40–79) and median ECOG
performance status 1. Largest histological subgroup was squamous
cell carcinoma. In all, 55 patients had pathologically proven stage
IIIa-N2 NSCLC, by mediastinoscopy (33), EUS-FNA (16), thor-
acotomy (4) and bronchoscopy with TBNA (2). Six patients were
assigned to stage IIIa-N2 on the basis of FDG-PET, CT-thorax and/
or expertise of a multidisciplinary team of lung cancer specialists.
Toxicity
All patients who started protocol treatment are evaluable for
toxicity. In total 169 courses of chemotherapy were administered,
with a median of three (range 1–4). Median relative dose intensity
(RDI) of cisplatin was 99.7% (range 49.7–105.3) and of epirubicin
100% (range 59.3–106.5). A dose reduction of cisplatin was
performed in 15 courses because of low creatinine clearance (12),
ototoxicity NCI-C grade II (1) and deterioriation of performance
status (2). Two of these 15 courses contained no cisplatin at all.
Epirubicin dose has been reduced in two courses due to
deterioriation of performance status. NCI-C grade III/IV leucocy-
topenia was reported in 35 courses (20.7%), NCI-C grade III/IV
thrombocytopenia in 26 courses (15.4%) and NCI-C grade III/IV
anaemia in six courses (3.6%). Neutropenic fever followed by
hospitalisation occurred in one patient and anaemia was corrected
by red blood cell transfusion in two patients. Nausea, vomiting and
alopecia were experienced frequently, but never higher than NCI-C
grade II/III.
Clinical response and restaging
Three patients were not evaluable because of interruption of
protocol treatment after one course due to leucocytopenia NCI-C
grade III/IV (2) and sepsis as a result of pneumonia (1), leaving 58
patients assessable for clinical response. There were no complete
remissions, a PR was observed in 28 patients, 24 had stable disease
and six patients progressed. The objective response rate (ORR) was
therefore 48.3% (95% CI: 36.0–61.1%).
Restaging was performed in evaluable patients without PD at
clinical response evaluation (n¼52). Owing to logistical reasons in
only 46 patients a restaging FDG-PET was performed. Twelve
patients underwent a mediastinoscopy, one of them also under-
went an EUS-FNA along with seven other patients. N2-positive
lymph nodes were detected in four (mediastinoscopy) and three
(EUS-FNA) procedures. Seventeen out of 19 patients who under-
went mediastinoscopy and/or EUS-FNA for restaging were also
evaluated by FDG-PET. Compared to mediastinoscopy and/or
EUS-FNA, FDG-PET predicted correct nodal status in 13 patients
(76.4%), was false-positive in two (11.8%) and false-negative in
two additional patients (11.8%).
Postinduction treatment
Median time to postinduction treatment was 51 days (range 10–
142), for surgery 49 days (range 10–142) and for radiotherapy 55
days (range 16–112). Table 2 summarises the postinduction
Table 1 Patient characteristics (n¼61)
Characteristic No. of patients %
Sex
Male 44 72.1
Female 17 27.9
Age (years)
Median 63
Range (40–79)
ECOG performance status
0 24 39.3
1 37 60.7
Histology
Squamous 29 47.5
Adenocarcinoma 18 29.5
Adenosquamous 1 1.6
Large cell 13 21.3
Clinical stage
Tx N2 M0 2 3.3
T1 N2 M0 12 19.7
T2 N2 M0 34 55.7
T3 N2 M0 13 21.3
Biopsy-proven N2-disease
Positive 55 90.2
Not performed 6 9.8
Clinical response
Partial response 28 48.3
Stable disease 24 41.4
Progressive disease 6 10.3
Not evaluable 3 —
Postinduction treatment
None 6 9.8
Surgery (resected) 24 39.3
Surgery (explored, no resection) 6 9.8
Radiotherapy 25 41.0
ECOG¼Eastern Cooperative Oncology Group.
Table 2 Postinduction treatment characteristics (n¼61)
Characteristic No. of patients %
Surgical procedure
Pneumonectomy 10 16.4
Lobectomy 13 21.3
Wedge resection 1 1.6
Exploration 6 9.8
Completeness of resection
R0 19
R1 5
Unresectable 6 9.8
Pathological staging
Complete response 1 1.6
T1-3 N0 M0 10 16.4
T1-3 N1 M0 4 6.6
T1-3 N2 M0 9 14.8
No specimens 6 9.8
Radiotherapy
After restaging
Radical 10 16.4
Palliative 15 24.6
After surgery
Radical 5 8.2
Palliative 4 6.6
No postinduction treatment 6 9.8
Multicenter phase II trial
ECJ Phernambucq et al
472
British Journal of Cancer (2006) 95(4), 470–474 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
streatment characteristics. In total 30 patients were approved for
surgery, including one patient who progressed under cisplatin/
epirubicin but had stable disease after three additional courses
of taxotere/gemcitabine. Six patients were surgically explored but
had no resection because of positive mediastinal lymph nodes
confirmed during thoracotomy (3) or progression to stage IIIb/IV
(3). Surgery with resection was performed in 24 patients, 10
patients had a pneumonectomy, 13 a lobectomy and one a wedge
resection.
Frequently encountered complications of surgery were anaemia,
atrial fibrillation and infectious complications (n¼9) of which two
had empyema. The latter patients fully recovered after treatment
with appropriate antibiotic therapy. Complete resection was
achieved in 19 patients, five resections were defined incomplete
because of microscopic residual disease. Pathological examination
of the resected specimens showed complete pathological response
in one patient and N2-disease in nine patients. Of those nine
patients, three had a negative mediastinoscopy and two a negative
EUS-FNA at restaging. Radical radiotherapy was administered
after resection to three patients. Patients who underwent
thoracotomy without resection were afterwards treated with
radical (2) or palliative (4) radiotherapy. After being restaged
negative for surgery, 25 patients proceeded to thoracic radio-
therapy (10radical and 15 palliative). Six patients did not have any
postinduction treatment due to deterioriation of performance
status.
Survival and disease-free survival time
Reference date for survival analysis was set at 1 May 2005 and at
that date 39 patients have died (63.9%). They died without
evidence of disease (5), with disease (26), from other cause (5) or
from unknown cause (3). Results of survival estimation are shown
in Figure 1. After a median follow-up period of 17 months, the
median duration of survival for all patients was 18 months (range
1–50þ), for resected patients 27 months (range 6–50) and for
patients treated with radiotherapy (including explored but
unresected patients) 14 months (range 1–34). In all, 34 patients
(55.7%) have developed a relapse of lung cancer, either in the lung
(17), brain (9), bone (3) or other sites (5). No evidence of disease
was reported for 17 patients (27.9%). Median disease-free survival
time was 11 months (range 3–28).
DISCUSSION
Although every chemotherapy regimen becomes more toxic in
higher dose, epirubicin at a dose of 135mgm
 2 can be given
without major side effects, provided G-CSF support is offered
(Huisman et al, 2001). In this trial leucocytopenia NCI-C grade III/
IV was observed in 20.7% of the courses but only one patient
developed neutropenic fever. Erythropoietin administration has
confirmed its preventive role during chemotherapy, since only
3.6% of all courses were associated with NCI-C grade III/IV
anaemia, in two of these patients followed by red blood cell
transfusion. No patients died during chemotherapy, and
both cisplatin and epirubicin were given with a median RDI of
almost 100%.
The results from clinical response, 28 PRs out of 58 evaluable
patients (ORR 48.3%, 95% CI: 36.0–61.1%), are in the same range
as comparable neoadjuvant cisplatin-based phase II trials: In a
study of 90 patients (stage IIIa N2 NSCLC) with docetaxel and
cisplatin, ORR was 66% (95% CI: 55–75%) (Betticher et al, 2003).
The Toronto trial (65 patients) with mitomycin, vindesine and
cisplatin for stage IIIa unresectable NSCLC reported an ORR of
67.7% (Burkes et al, 2005) and a trial (47 patients) of gemcitabine
and cisplatin for biopsy-proven stage IIIa-N2 NSCLC reported an
ORR of 70.2% (95% CI: 55.1–82.7%) (Van Zandwijk et al, 2000).
Finally, a trial (42 patients) of gemcitabine–cisplatin–paclitaxel
for stage IIIa(N2)/IIIb inoperable NSCLC reported an ORR of 71%
(95% CI: 57.2–84.7%) (Cappuzzo et al, 2003). In particular, an
analysis of the EORTC 08941 phase III study which used a variety
of induction chemotherapies in stage IIIa-N2 NSCLC reported an
ORR of 59% (95% CI: 54–64%) for cisplatin containing regimens
(Van Meerbeeck et al, 2003). Accurate response assessment after
induction treatment is crucial, since only those patients with
mediastinal downstaging will benefit most of surgery. CT-thorax
often underestimates pathological response (Lee et al, 2000;
Margaritora et al, 2001). Another option is FDG-PET, which role
in NSCLC is not fully understood. Hoekstra et al (2005) reported
that after one course of induction chemotherapy for patients with
stage pIIIa-N2 NSCLC, responders and nonresponders can be
separated by FDG-PET. However, assessment of pathological
response in the mediastinal lymph nodes is not reliable. Two
small studies compared surgical staging with FDG-PET and
reported that after induction therapy, a correct nodal status
was predicted by FDG-PET in 48–52% (Akhurst et al, 2002; Port
et al, 2004). In this trial, 19 patients underwent restaging
with mediastinoscopy and/or EUS-FNA and 17 of these had
also been evaluated by FDG-PET. Prediction of nodal status was
correct in 13 patients (76.4%), overstaged in two (11.8%) and
understaged in two patients (11.8%). The role of FDG-PET as
predictor of pathological response after induction therapy for
NSCLC is unclear and has to be investigated in trials with larger
patient numbers.
The most important prognostic factor for survival is the
presence of N2-disease after induction therapy. Eradicated
nodal status is related to higher survival rates (De Leyn et al,
1999; Bueno et al, 2000; Sawabata et al, 2003). At present,
N2-disease can only be accurately detected by pathological
response evaluation. Mediastinoscopy is a good option for this
purpose, but more techniques are available, especially EUS-FNA. A
recent study reported that the combination of mediastinoscopy
and EUS-FNA detected more patients with N2-disease than
mediastinoscopy alone (Annema et al, 2005). In our study,
seven patients with negative mediastinoscopy had a resection
and pathological examination of the specimens showed
N2-disease in three (42.9%) patients. Endoscopic ultrasound-
guided fine-needle aspiration was negative for five patients,
they all had a resection, and their pathological examination
showed N2-disease in two (40%) patients. Endoscopic ultrasound-
guided fine-needle aspiration is an useful method for pathological
staging in NSCLC and its role has to be defined for response
evaluation.
Median time to postinduction treatment was 51 days (range
10–142). It is likely that this would have implications for survival
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Figure 1 Overall survival (n¼61).
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sdue to accelerated repopulation after chemotherapy (Kim and
Tannock, 2005). Compared to the EORTC 08941 study (Van
Meerbeeck et al, 2005), the median time to postinduction
treatment is identical (51 days, range 17–113).
Median survival for all 61 patients in this trial is 18 months
(range 1–50þ) and 27 months for resected patients, this is similar
to the studies mentioned before.
In conclusion, response rate of accelerated cisplatin and high-
dose epirubicin as induction chemotherapy for stage IIIa-N2
NSCLC patients is not different from more commonly used
cisplatin-based regimen. Based on the statistical design of this
study that rejects further exploration at a response rate of 55% or
less, investigating this chemotherapy combination in phase III
trials is not recommended.
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